Less than 40% of patient advocacy groups have favorable view of pharma industry

Listen
Text
  • Small
  • Medium
  • Large

A new report conducted by Patient View explores the corporate reputation of the pharmacy industry from the patient perspective.

For the report, researchers polled 1,463 patient groups representing more than 46 specialties from 105 countries. The patient groups were polled on their perceptions of and relationships with 47 pharmaceutical companies from November 2016 to early-February 2017.

Here are five things to know.

1. Only 37.9 percent of respondents said the drug industry had an "excellent" or "good" corporate reputation in 2016, compared to 44.7 percent of respondents who shared the same favorable view of the industry in 2015.

2. In 2016, 23 percent of patient groups thought the drug industry's corporate reputation improved over the last five years. In 2015, 28 percent of respondents had the same response.

3. When rated on pharma's ability to produce high-quality, useful products, 64 percent of patient groups said the industry was "good" or "excellent," compared to 72 percent a year prior.

4. One-fourth of respondents said the drug industry was "good" or "excellent" at ethical marketing, while 36 percent held the same view in 2015.

5. When asked to rate the drug industry's ability to be innovative, 59 percent of patient groups said pharma was "good" or "excellent" in 2016, compared to 69 percent who said the same thing a year prior.

To view the full report, click here.

More articles on supply chain:

Trump calls for drug cost measure in AHCA
FDA approves Allergan's dermal filler: 4 things to know
Study: Amgen cholesterol drug lowers risk of heart disease, stroke by 20%

 

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.